

## Your request

You requested the following:

1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?
  - a) Avelumab
  - b) Atezolizumab
  - c) Carboplatin with Gemcitabine
  - d) Carboplatin single or in any other combination
  - e) Cisplatin with Gemcitabine
  - f) Cisplatin single or in any other combination
  - g) Nivolumab
  - h) Pembrolizumab
  - i) Any other systemic anti-cancer therapy
  - j) Palliative care only
  
2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
  
3. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?
  - a) Afibercept
  - b) Bevacizumab
  - c) Capecitabine
  - d) CAPIRI
  - e) CAPOX (XELOX)
  - f) Cetuximab in combination with FOLFIRI/FOLFOX
  - g) Cetuximab not in combination with FOLFIRI or FOLFOX
  - h) Irinotecan only
  - i) FOLFIRI
  - j) FOLFOX
  - k) Fluorouracil (5FU) only
  - l) Oxaliplatin only
  - m) Nivolumab
  - n) Panitumumab in combination with FOLFIRI/FOLFOX
  - o) Panitumumab not in combination with FOLFIRI or FOLFOX
  - p) Pembrolizumab
  - q) Raltitrexed
  - r) Ramucirumab
  - s) Regorafenib
  - t) Tegafur + Uracil
  - u) Any other systemic anti-cancer therapy
  - v) Palliative care only

## **Our response**

1. We do not hold the information requested for points 1a to 1i. You may wish to direct your request to [Velindre University NHS Trust](#), which delivers Chemotherapy and Radiotherapy treatment on behalf of the Health Board for these patients.

Our response to question 1j is 6 patients.

2. We do not participate in any clinical trials for the treatment of Urothelial cancer.
3. We do not hold the information requested for points 2a to 2u. You may wish to direct your request to [Velindre University NHS Trust](#), which delivers Chemotherapy and Radiotherapy treatment on behalf of the Health Board for these patients.

Our response to question 2v is 20 patients.